Functional Characterization of 5-HT1B Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR

In the present study, we used a simultaneous PET-MR experimental design to investigate the effects of functionally different compounds (agonist, partial agonist, and antagonist) on 5-HT1B receptor (5-HT1BR) occupancy and the associated hemodynamic responses. In anesthetized male nonhuman primates (n = 3), we used positron emission tomography (PET) imaging with the radioligand [11C]AZ10419369 administered as a bolus followed by constant infusion to measure changes in 5-HT1BR occupancy. Simultaneously, we measured changes in cerebral blood volume (CBV) as a proxy of drug effects on neuronal activity. The 5-HT1BR partial agonist AZ10419369 elicited a dose-dependent biphasic hemodynamic response that was related to the 5-HT1BR occupancy. The magnitude of the response was spatially overlapping with high cerebral 5-HT1BR densities. High doses of AZ10419369 exerted an extracranial tissue vasoconstriction that was comparable to the less blood–brain barrier-permeable 5-HT1BR agonist sumatriptan. By contrast, injection of the antagonist GR127935 did not elicit significant hemodynamic responses, even at a 5-HT1BR cerebral occupancy similar to the one obtained with a high dose of AZ10419369. Given the knowledge we have of the 5-HT1BR and its function and distribution in the brain, the hemodynamic response informs us about the functionality of the given drug: changes in CBV are only produced when the receptor is stimulated by the partial agonist AZ10419369 and not by the antagonist GR127935, consistent with low basal occupancy by endogenous serotonin. SIGNIFICANCE STATEMENT We here show that combined simultaneous positron emission tomography and magnetic resonance imaging uniquely enables the assessment of CNS active compounds. We conducted a series of pharmacological interventions to interrogate 5-HT1B receptor binding and function and determined blood–brain barrier passage of drugs and demonstrate target involvement. Importantly, we show how the spatial and temporal effects on brain hemodynamics provide information about pharmacologically driven downstream CNS drug effects; the brain hemodynamic response shows characteristic dose-related effects that differ depending on agonistic or antagonistic drug characteristics and on local 5-HT1B receptor density. The technique lends itself to a comprehensive in vivo investigation and understanding of drugs' effects in the brain.

[1]  C. Svarer,et al.  Serotonin 1B Receptor Binding Is Associated With Trait Anger and Level of Psychopathy in Violent Offenders , 2017, Biological Psychiatry.

[2]  Richard Baumgartner,et al.  Evaluation of an fMRI USPIO‐based assay in healthy human volunteers , 2017, Journal of magnetic resonance imaging : JMRI.

[3]  R. Hargreaves,et al.  Challenges in developing drugs for primary headaches , 2017, Progress in Neurobiology.

[4]  P. Svenningsson,et al.  Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia – An autoradiography study , 2017, European Neuropsychopharmacology.

[5]  Ciprian Catana,et al.  Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI , 2016, Neuropsychopharmacology.

[6]  phMRI: methodological considerations for mitigating potential confounding factors , 2015, Front. Neurosci..

[7]  C. Lindsley,et al.  New statistics on the cost of new drug development and the trouble with CNS drugs. , 2014, ACS chemical neuroscience.

[8]  Lars Farde,et al.  Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain , 2014, NeuroImage.

[9]  Pradeep J Nathan,et al.  Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. , 2014, Current opinion in pharmacology.

[10]  C. Yokoyama,et al.  A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques , 2014, Translational Psychiatry.

[11]  Gary Glover,et al.  Ferumoxytol enhanced resting state fMRI and relative cerebral blood volume mapping in normal human brain , 2013, NeuroImage.

[12]  Yiyun Huang,et al.  Awake Nonhuman Primate Brain PET Imaging with Minimal Head Restraint: Evaluation of GABAA-Benzodiazepine Binding with 11C-Flumazenil in Awake and Anesthetized Animals , 2013, The Journal of Nuclear Medicine.

[13]  Julian Macoveanu,et al.  Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala , 2013, Journal of psychopharmacology.

[14]  Ciprian Catana,et al.  Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI , 2013, Proceedings of the National Academy of Sciences.

[15]  Ciprian Catana,et al.  PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.

[16]  Thomas Christen,et al.  Contrast-enhanced functional blood volume imaging (CE-fBVI): Enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol , 2012, NeuroImage.

[17]  Joseph B. Mandeville,et al.  IRON fMRI measurements of CBV and implications for BOLD signal , 2012, NeuroImage.

[18]  Bruce G. Jenkins,et al.  Pharmacologic magnetic resonance imaging (phMRI): Imaging drug action in the brain , 2012, NeuroImage.

[19]  Paul M. Matthews,et al.  Positron emission tomography molecular imaging for drug development. , 2012, British journal of clinical pharmacology.

[20]  J. Olesen,et al.  Effect of CGRP and sumatriptan on the BOLD response in visual cortex , 2012, The Journal of Headache and Pain.

[21]  J. Detre,et al.  Potentials and Challenges for Arterial Spin Labeling in Pharmacological Magnetic Resonance Imaging , 2011, Journal of Pharmacology and Experimental Therapeutics.

[22]  Ciprian Catana,et al.  Toward Implementing an MRI-Based PET Attenuation-Correction Method for Neurologic Studies on the MR-PET Brain Prototype , 2010, The Journal of Nuclear Medicine.

[23]  Richard E Carson,et al.  High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943. , 2010, Nuclear medicine and biology.

[24]  Z. Bhagwagar,et al.  The 5-HT1B receptor: a novel target for the pathophysiology of depression. , 2009, Current drug targets.

[25]  L. Mrzljak,et al.  [N-methyl-3H3]AZ10419369 Binding to the 5-HT1B Receptor: In Vitro Characterization and in Vivo Receptor Occupancy , 2009, Journal of Pharmacology and Experimental Therapeutics.

[26]  Christer Halldin,et al.  [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain , 2008, NeuroImage.

[27]  P. Boesiger,et al.  GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI , 2007, Nature Neuroscience.

[28]  K. Miczek,et al.  Anti-aggressive effects of agonists at 5-HT1B receptors in the dorsal raphe nucleus of mice , 2007, Psychopharmacology.

[29]  Yun Zhou,et al.  An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge , 2006, NeuroImage.

[30]  M. Pomper,et al.  Positron emission tomography in molecular imaging , 2004, IEEE Engineering in Medicine and Biology Magazine.

[31]  Y. Sari Serotonin1B receptors: from protein to physiological function and behavior , 2004, Neuroscience & Biobehavioral Reviews.

[32]  D. Hoyer,et al.  How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  S. Ross,et al.  Failure to detect in vivo inverse agonism of the 5-HT1B receptor antagonist SB-224289 in 5-HT-depleted guinea-pigs , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[34]  D. Middlemiss,et al.  SB-236057-A: a selective 5-HT1B receptor inverse agonist. , 2006, CNS drug reviews.

[35]  E. Hamel,et al.  Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles , 2001, British journal of pharmacology.

[36]  J. Williams,et al.  Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. , 2000, Molecular pharmacology.

[37]  J. Pickard,et al.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. , 1999, British journal of clinical pharmacology.

[38]  L. Descarries,et al.  Endothelial expression of the 5-hydroxytryptamine1B antimigraine drug receptor in rat and human brain microvessels , 1998, Neuroscience.

[39]  B. Rosen,et al.  Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation , 1998, Magnetic resonance in medicine.

[40]  P. Pauwels,et al.  Pharmacological analysis of G‐protein activation mediated by guinea‐pig recombinant 5‐HT1B receptors in C6‐glial cells: similarities with the human 5‐HT1B receptor , 1998, British journal of pharmacology.

[41]  J. Palacios,et al.  Characterization of human serotonin 1D and 1B receptors using [ 3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  S. J. Starkey,et al.  GR127935: a potent and selective 5-HT1D receptor antagonist , 1995, Behavioural Brain Research.

[43]  M. Geyer Serotonergic functions in arousal and motor activity , 1995, Behavioural Brain Research.

[44]  Cocaine enhancement of the action of 5-hydroxytryptamine in rat cingulate cortex in vitro , 1993, Neuroscience Letters.

[45]  B. Rosen,et al.  Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.